🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Simple clinical features can be used to help better target treatment in type 2 diabetes. Findings from our double-blind three-way crossover trial, Trimaster are published in Nature Medicine today and presented at the IDF congress #IDF2022 nature.com/articles/s4159….

Using a randomised three-way crossover design and stratification approaches, the TriMaster study demonstrated that patients with obesity and type 2 #diabetes were more likely to have greater glycaemic control with pioglitazone than on sitagliptin #IDF2022 nature.com/articles/s4159…

A secondary analysis from the TriMaster study demonstrates that after trying 3 different classes of #diabetes medications, most patients preferentially selected the drug that was associated with the best glycaemic control on an individual level #IDF2022 nature.com/articles/s4159…

Modifiable risk factors are consistently associated with severe influenza, pneumonia and #COVID19 infection outcomes in people with type 2 #diabetes. #T2D Read more about the latest research 👉 easd-elearning.org/type-2-diabete…

New research from Nicholas John Meyrick Thomas ExeterDiabetes just published in Diabetes Care, a research journal of the ADA 🌟 shows that the presentation, genetic susceptability and rate of C-peptide loss of robustly defined adult-onset type 1 diabetes is not altered by onset age tinyurl.com/2ckjhbka

Exciting new PhD opportunity in our friendly and supportive team using statistical modelling of electronic healthcare records to develop precision medicine approaches for long term outcomes in Type 2 diabetes. exeter.ac.uk/study/funding/…

2 fantastic #DataScience PhDs available Exeter Med School on #type2diabetes precision medicine with world-leading & inspiring (from experience!) supervision incl. Beverley Shields 1. Precision medicine methods tinyurl.com/mt8v7vjh 2. Precision medicine models tinyurl.com/s6ym239s

Great #DUKPC talk from Katie Young ExeterDiabetes - precision medicine to assess the individualised heart failure benefit of SGLT2-inhibitors for people with #type2diabetes

Huge congratulations to star Exeter Med School PhD student Pedro Cardoso, winner of the Diabetes UK Early Career Investigator award at #DUKPC2023 for research on precision medicine in #type2diabetes ExeterDiabetes

Well done Pedro!! Exeter Med School ExeterDiabetes #DUKPC2023

Well done to Smruthy for her excellent Poster award! ⁦⁩ Exeter Med School⁩ ⁦ExeterDiabetes⁩ and

Huge congrats to Jiayi on a fantastic MSc Health Data Science project presentation! Was a joy to supervise you together with Katie Young Exeter Med School. I’m sure we will see great things from you in the future!

📊 OUT NOW Communications Medicine - Young et al. review the evidence on #T2D treatment effect heterogeneity with #GLP1 receptor agonists and #SGLT2 inhibitors | Katie Young Adem yesuf Angus Jones John Dennis Ewan Pearson Exeter Med School UoD Medicine #PMDI nature.com/articles/s4385…

Out now! cardiab.biomedcentral.com/articles/10.11… We show that, based on recent NICE guidelines, 93% of T2Ds in England could be eligible for SGLT2i, at a cost of >£1b. This is despite most having no pre-existing ASCVD; a group largely excluded from SGLT2i CVD trials. More details below ⤵️

Precision medicine in #type2diabetes: Cardoso et al develop a new approach for phenotype-based targeting of SGLT2-inhibitors and GLP1-receptor agonists tinyurl.com/bp89t8aa🔓 Exeter Med School John Dennis Angus Jones